Literature DB >> 16815102

Mitochondrial disease activates transcripts of the unfolded protein response and cell cycle and inhibits vesicular secretion and oligodendrocyte-specific transcripts.

Gino Cortopassi1, Steven Danielson, Mansour Alemi, Shan Shan Zhan, Warren Tong, Valerio Carelli, Andrea Martinuzzi, Sangot Marzuki, Kari Majamaa, Alice Wong.   

Abstract

Mutations in gene products expressed in the mitochondrion cause a nuclear transcriptional response that leads to neurological disease. To examine the extent to which the transcriptional profile was shared among 5 mitochondrial diseases (LHON, FRDA, MELAS, KSS, and NARP), we microarrayed mutant and control groups in N-tera2, SH-SY5Y, lymphoblasts, fibroblasts, myoblasts, muscle, and osteosarcoma cybrids. Many more transcripts were observed to be significantly altered and shared among these 5 mitochondrial diseases and cell types than expected on the basis of random chance, and these genes are significantly clustered with respect to biochemical pathways. Mitochondrial disease activated multiple transcripts of the unfolded protein response (UPR), and of the cell cycle pathway, and low doses of the mitochondrial inhibitor rotenone induced UPR transcripts in the absence of cell death. By contrast, functional clusters inhibited by mitochondrial disease included: vesicular secretion, protein synthesis, and oligodendrogenesis. As it is known that UPR activation specifically inhibits vesicular secretion and protein synthesis, these data support the view that mitochondrial disease and dysfunction triggers the UPR, which in turn causes secretory defects which inhibit cellular migratory, synaptic, and oligodendrocytic functions, providing a testable hypothesis for how mitochondrial dysfunction causes disease. Since ischemic hypoxia, chemical hypoxia, and mitochondrial genetic disease (which could be considered 'genetic hypoxia') produce an overlapping induction of UPR and cell cycle genes which appears to have negative consequences, the modulation of these responses might be of benefit to patients with mitochondrial disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16815102     DOI: 10.1016/j.mito.2006.05.002

Source DB:  PubMed          Journal:  Mitochondrion        ISSN: 1567-7249            Impact factor:   4.160


  20 in total

1.  Ethambutol induced toxic optic neuropathy in HIV positive patients.

Authors:  Hamzah Mustak; Graeme Rogers; Colin Cook
Journal:  Int J Ophthalmol       Date:  2013-08-18       Impact factor: 1.779

2.  Altered Oligodendrocyte Maturation and Myelin Maintenance: The Role of Antiretrovirals in HIV-Associated Neurocognitive Disorders.

Authors:  Brigid K Jensen; Hubert Monnerie; Maggie V Mannell; Patrick J Gannon; Cagla Akay Espinoza; Michelle A Erickson; Annadora J Bruce-Keller; Benjamin B Gelman; Lisa A Briand; R Christopher Pierce; Kelly L Jordan-Sciutto; Judith B Grinspan
Journal:  J Neuropathol Exp Neurol       Date:  2015-11       Impact factor: 3.685

3.  Clinical and electrophysiology findings in Slovene patients with Leber hereditary optic neuropathy.

Authors:  Martina Jarc-Vidmar; Mojca Tajnik; Jelka Brecelj; Ana Fakin; Maja Sustar; Mateja Naji; Branka Stirn-Kranjc; Damjan Glavač; Marko Hawlina
Journal:  Doc Ophthalmol       Date:  2015-02-19       Impact factor: 2.379

4.  Mitochondrial DNA deletions inhibit proteasomal activity and stimulate an autophagic transcript.

Authors:  Mansour Alemi; Alessandro Prigione; Alice Wong; Robert Schoenfeld; Salvatore DiMauro; Michio Hirano; Franco Taroni; Gino Cortopassi
Journal:  Free Radic Biol Med       Date:  2006-09-19       Impact factor: 7.376

5.  Frataxin knockdown causes loss of cytoplasmic iron-sulfur cluster functions, redox alterations and induction of heme transcripts.

Authors:  Chunye Lu; Gino Cortopassi
Journal:  Arch Biochem Biophys       Date:  2006-10-04       Impact factor: 4.013

6.  Oligodendroglial differentiation induces mitochondrial genes and inhibition of mitochondrial function represses oligodendroglial differentiation.

Authors:  Robert Schoenfeld; Alice Wong; Jillian Silva; Ming Li; Aki Itoh; Makoto Horiuchi; Takayuki Itoh; David Pleasure; Gino Cortopassi
Journal:  Mitochondrion       Date:  2009-12-22       Impact factor: 4.160

Review 7.  Mitochondrial medicine for neurodegenerative diseases.

Authors:  Heng Du; Shirley ShiDu Yan
Journal:  Int J Biochem Cell Biol       Date:  2010-01-11       Impact factor: 5.085

8.  Evaluation of the Acquisition of the Aerobic Metabolic Capacity by Myelin, during its Development.

Authors:  Silvia Ravera; Martina Bartolucci; Patrizia Garbati; Sara Ferrando; Daniela Calzia; Paola Ramoino; Maurizio Balestrino; Alessandro Morelli; Isabella Panfoli
Journal:  Mol Neurobiol       Date:  2015-12-16       Impact factor: 5.590

9.  Mitochondrial biogenesis drives a vicious cycle of metabolic insufficiency and mitochondrial DNA deletion mutation accumulation in aged rat skeletal muscle fibers.

Authors:  Allen Herbst; Chad J Johnson; Kayla Hynes; Debbie McKenzie; Judd M Aiken
Journal:  PLoS One       Date:  2013-03-13       Impact factor: 3.240

Review 10.  Mitochondria Retrograde Signaling and the UPR mt: Where Are We in Mammals?

Authors:  Thierry Arnould; Sébastien Michel; Patricia Renard
Journal:  Int J Mol Sci       Date:  2015-08-06       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.